The “real-life” variability of CA-125 in ovarian cancer patients

Tso, E.; Elson, Paul; VanLente, Frederick; Markman, Maurie

doi:10.1016/j.ygyno.2006.02.010

Cited by 9 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Area under pain curve Subjective/subject to recall Requires patient to report pain, which is a subjective measure and could report the same pain differently at a different time/by a different method or if previous scores were not provided [56], and recall incorrectly [57] CA125 Biological variability/ laboratory error Assay imprecision can contribute considerably to result variations in a conventional laboratory setting [58] and changes can occur due to normal biological variation [59] Creatinine on admission…”

Section: Predictor Key Reasons Explanationmentioning

confidence: 99%

Measurement error and timing of predictor values for multivariable risk prediction models are poorly reported

Whittle

Peat

Belcher

et al. 2018

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

show abstract

Section: Predictor Key Reasons Explanationmentioning

confidence: 99%

Measurement error and timing of predictor values for multivariable risk prediction models are poorly reported

Whittle

Peat

Belcher

et al. 2018

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

show abstract

“…3Y5 A primary issue with evaluating the clinical utility of the CA-125 antigen level is reliability. 3 Prior studies have suggested that the diagnostic relevance of the tumor marker reflects the patient's clinical condition and biological variation and that consistent increases correspond to disease progression or severity. 3,6,7 Because there is great difficulty in determining the significance of a single laboratory value that can be associated with extreme variability, 8Y11 patient management options reflecting CA-125 values should be exercised with discretion.…”

mentioning

confidence: 99%

Clinical Utility of CA-125 for Maintenance Therapy in the Treatment of Advanced Stage Ovarian Carcinoma

Micha

Goldstein

Rettenmaier

et al. 2009

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

Maintenance therapy has been extensively studied to discern any prospective therapeutic advantage in the treatment of advanced stage ovarian carcinoma. The CA-125 assay may have prognostic benefit in determining whether this treatment regimen is appropriate for ovarian carcinoma patients who achieve a complete response to first-line therapy. We retrospectively documented the CA-125 levels of 2 advanced ovarian cancer patient groups who exhibited a clinically defined complete response to their primary induction therapy. Patients were then treated with a paclitaxel-based maintenance therapy regimen. The first group (group A; n = 13 patients) received 3 cycles of single-agent paclitaxel maintenance therapy, and the second group (group B; n = 13 patients) received 12 cycles of single-agent paclitaxel maintenance therapy. The premaintenance therapy CA-125 serum levels (<10 or > or =10 U/mL) of the 2 treatment groups were then retrospectively evaluated in an intragroup analysis to discern any relationship with progression-free survival (PFS) and overall survival. There was a statistically significantly relationship between the CA-125 levels (<10 U/mL) premaintenance therapy and PFS. The patients who had the lowest CA-125 levels exhibited the most favorable PFS results. Despite the limited sample size and nonrandomized nature of this study, these results are provocative and suggest that advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy with a CA-125 serum level less than 10 U/mL may be more amenable to the benefits of paclitaxel maintenance therapy.

show abstract

“…TM levels obtained from peripheral blood samples were measured before TKI targeted therapy and after 7 and 14 days of treatment. To reduce TM levels' influence with inherent intra-individual biological variation and within-laboratory coefficients of variation (TM v ) [20][21][22], we defined a cutoff level for each individual using pre-treatment TM levels of 2-fold over the standard upper limit. Therefore, enrollment criteria included CEA, CA125, CA19-9, and CA15-3 levels at 10.0 ng/mL, 70 units/mL, 70 units/mL, and 76 units/mL, respectively.…”

Section: Serum Cea Ca125 Ca19-9 and Ca15-3 Level Detection And Anamentioning

confidence: 99%

Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma

Chen¹,

Huang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Objective Image evaluation strategy for lung cancer patients has difficulty obtaining the appropriate quantity of diffuse lung nodules and bone metastases. The study was to demonstrate whether early variations in the levels of serum 4-tumor markers (4-TMs)(carcinoembryonic antigen [CEA], cancer antigen [CA]125, CA19-9, and CA15-3) after TKI targeted therapy were associated with treatment response in patients with lung adenocarcinoma. Methods Patients with stage IIIB-IV lung adenocarcinoma taking epidermal growth factor receptor (EGFR) TKIs or anaplastic lymphoma kinase (ALK) inhibitors were enrolled prospectively from June 2012 to February 2015. According to the variations of the percentage of change in 4-TM levels (4-TMpc), we divided patients into ascending (increases in 4-TMpc over the 7th- 14th day) and descending (decreases in 4-TMpc over the 7th- 14th day) groups. Results 184 patients were enrolled, and 89% had at least one of the pre-treatment evaluable TMs and were further analyzed. An excellent response to the TKI targeted therapy was accurately predicted in the descending group, as determined using receiver operating characteristic curve analysis (an area under the curve, 0.83). Multivariate Cox hazards model analyses demonstrated that the type of 4-TMpc and mutation status were the strongest predictors of progression-free survival (PFS)(descending versus ascending, hazard ratios [HR] 0.30, 95% confidence interval [CI], 0.19–0.47; sensitive mutation versus wide type, HR 0.30, 95% CI, 0.19–0.48). Conclusions Type of 4-TMpc 14 days after TKI targeted therapy is associated with an image response and PFS, without regarding mutation status, in patients with advanced lung adenocarcinoma.

show abstract

The “real-life” variability of CA-125 in ovarian cancer patients

Cited by 9 publications

References 12 publications

Measurement error and timing of predictor values for multivariable risk prediction models are poorly reported

Measurement error and timing of predictor values for multivariable risk prediction models are poorly reported

Clinical Utility of CA-125 for Maintenance Therapy in the Treatment of Advanced Stage Ovarian Carcinoma

Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma

Contact Info

Product

Resources

About